cav1 2  (Alomone Labs)


Bioz Verified Symbol Alomone Labs is a verified supplier
Bioz Manufacturer Symbol Alomone Labs manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Alomone Labs cav1 2
    Cav1 2, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cav1 2/product/Alomone Labs
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    cav1 2 - by Bioz Stars, 2023-02
    93/100 stars

    Images

    cav1 2  (Alomone Labs)


    Bioz Verified Symbol Alomone Labs is a verified supplier
    Bioz Manufacturer Symbol Alomone Labs manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Alomone Labs cav1 2
    Cav1 2, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cav1 2/product/Alomone Labs
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    cav1 2 - by Bioz Stars, 2023-02
    93/100 stars

    Images

    immunofluorescence  (Alomone Labs)


    Bioz Verified Symbol Alomone Labs is a verified supplier
    Bioz Manufacturer Symbol Alomone Labs manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 92

    Structured Review

    Alomone Labs immunofluorescence
    Immunofluorescence, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/immunofluorescence/product/Alomone Labs
    Average 92 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    immunofluorescence - by Bioz Stars, 2023-02
    92/100 stars

    Images

    anti trpv3 antibody  (Alomone Labs)


    Bioz Verified Symbol Alomone Labs is a verified supplier
    Bioz Manufacturer Symbol Alomone Labs manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Alomone Labs anti trpv3 antibody
    (a) Acute itch behaviors of <t>Trpv3−/−</t> mice and their WT littermates induced by intradermal injections of SLIGRL (50 μg), trypsin (100 μg), 2fly (10 μg), histamine (200 μg), and BAM 8-22 (150 μg). Unpaired t tests. n = 6–8. (b) WT mice were pre-injected with vehicle (Veh) (8% DMSO), 74a (150 μg, i.d.) or FSLLRY (100 μg, i.d.) 15 min before testing the scratching behaviors elicited by SLIGRL, trypsin, or 2fly. One-way ANOVA followed by Tukey’s post hoc. n = 6-8 mice per group. (c) TRPV3 expression in the skin and DRG of Trpv3+/+ and Trpv3−/− mice as determined by western blot. (d) Double immunofluorescence staining of PAR2 (green) and TRPV3 (red) in mouse keratinocytes. Scale bar, 20 μm. (e) Venn diagram showing the overlapping of PAR2 and TRPV3 in mouse keratinocytes. *p < 0.05, **p < 0.01, ***p < 0.001. Data are presented as mean ± s.e.m.
    Anti Trpv3 Antibody, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti trpv3 antibody/product/Alomone Labs
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti trpv3 antibody - by Bioz Stars, 2023-02
    93/100 stars

    Images

    1) Product Images from "PAR2 mediates itch via TRPV3 signaling in keratinocytes"

    Article Title: PAR2 mediates itch via TRPV3 signaling in keratinocytes

    Journal: The Journal of investigative dermatology

    doi: 10.1016/j.jid.2020.01.012

    (a) Acute itch behaviors of Trpv3−/− mice and their WT littermates induced by intradermal injections of SLIGRL (50 μg), trypsin (100 μg), 2fly (10 μg), histamine (200 μg), and BAM 8-22 (150 μg). Unpaired t tests. n = 6–8. (b) WT mice were pre-injected with vehicle (Veh) (8% DMSO), 74a (150 μg, i.d.) or FSLLRY (100 μg, i.d.) 15 min before testing the scratching behaviors elicited by SLIGRL, trypsin, or 2fly. One-way ANOVA followed by Tukey’s post hoc. n = 6-8 mice per group. (c) TRPV3 expression in the skin and DRG of Trpv3+/+ and Trpv3−/− mice as determined by western blot. (d) Double immunofluorescence staining of PAR2 (green) and TRPV3 (red) in mouse keratinocytes. Scale bar, 20 μm. (e) Venn diagram showing the overlapping of PAR2 and TRPV3 in mouse keratinocytes. *p < 0.05, **p < 0.01, ***p < 0.001. Data are presented as mean ± s.e.m.
    Figure Legend Snippet: (a) Acute itch behaviors of Trpv3−/− mice and their WT littermates induced by intradermal injections of SLIGRL (50 μg), trypsin (100 μg), 2fly (10 μg), histamine (200 μg), and BAM 8-22 (150 μg). Unpaired t tests. n = 6–8. (b) WT mice were pre-injected with vehicle (Veh) (8% DMSO), 74a (150 μg, i.d.) or FSLLRY (100 μg, i.d.) 15 min before testing the scratching behaviors elicited by SLIGRL, trypsin, or 2fly. One-way ANOVA followed by Tukey’s post hoc. n = 6-8 mice per group. (c) TRPV3 expression in the skin and DRG of Trpv3+/+ and Trpv3−/− mice as determined by western blot. (d) Double immunofluorescence staining of PAR2 (green) and TRPV3 (red) in mouse keratinocytes. Scale bar, 20 μm. (e) Venn diagram showing the overlapping of PAR2 and TRPV3 in mouse keratinocytes. *p < 0.05, **p < 0.01, ***p < 0.001. Data are presented as mean ± s.e.m.

    Techniques Used: Injection, Expressing, Western Blot, Double Immunofluorescence Staining

    (a) The percentages of responding keratinocytes from WT and Trpv3−/− mice stimulated with histamine (100 μM) and SLIGRL (50 μM). ***p < 0.001, unpaired t tests. n = 3 mice per group. (b) Representative fluorescence images of Fura2 (2 μM)-loaded WT, Trpv3−/− and Par2−/− keratinocytes stimulated with SLIGRL (50 μM). Scale bar, 20 μm. (c) Representative traces showing intracellular Ca2+ responses elicited by SLIGRL (50 μM) in WT mouse keratinocytes. (d, e) The effect of FSLLRY (100 μM) (d) and 74a (100 μM) (e) on SLIGRL-induced Ca2+ responses in WT mouse keratinocytes. (f) The effect of 74a (100 μM) on SLIGKV-induced (100 μM) Ca2+responses in human keratinocytes. (g) Quantified data showing the percentages of SLIGRL-responsive keratinocytes before and after the incubation of FSLLRY or 74a. ***p < 0.001, unpaired t test, n = 3 mice per group. Data are presented as mean ± s.e.m.
    Figure Legend Snippet: (a) The percentages of responding keratinocytes from WT and Trpv3−/− mice stimulated with histamine (100 μM) and SLIGRL (50 μM). ***p < 0.001, unpaired t tests. n = 3 mice per group. (b) Representative fluorescence images of Fura2 (2 μM)-loaded WT, Trpv3−/− and Par2−/− keratinocytes stimulated with SLIGRL (50 μM). Scale bar, 20 μm. (c) Representative traces showing intracellular Ca2+ responses elicited by SLIGRL (50 μM) in WT mouse keratinocytes. (d, e) The effect of FSLLRY (100 μM) (d) and 74a (100 μM) (e) on SLIGRL-induced Ca2+ responses in WT mouse keratinocytes. (f) The effect of 74a (100 μM) on SLIGKV-induced (100 μM) Ca2+responses in human keratinocytes. (g) Quantified data showing the percentages of SLIGRL-responsive keratinocytes before and after the incubation of FSLLRY or 74a. ***p < 0.001, unpaired t test, n = 3 mice per group. Data are presented as mean ± s.e.m.

    Techniques Used: Fluorescence, Incubation

    (a-c) Representative traces showing that Ca2+ transients elicited by SLIGRL (50 μM) in WT mouse keratinocytes were completely inhibited by co-incubation with 100 μM gallein, a Gβγ-protein inhibitor (a) and 10 μM U73122, a PLC inhibitor (b), but were partially inhibited by co-incubation with 10 μM DBHQ, an ATPase inhibitor (c). (d) Quantified data showing the percentages of SLIGRL-responsive keratinocytes before and after the incubation of gallein, U73122 or DBHQ. *p < 0.05, **p < 0.01, ***p < 0.001, unpaired t test, n = 3 mice per group. (e) TSLP in cultured media after SLIGRL stimulation was assayed by ELISA. Keratinocytes from Trpv3−/− and Par2−/− mice released less TSLP in response to SLIGRL stimulation. n = 3 mice per group. *p < 0.05, **p < 0.01, two-way ANOVA with Bonferroni post hoc test.
    Figure Legend Snippet: (a-c) Representative traces showing that Ca2+ transients elicited by SLIGRL (50 μM) in WT mouse keratinocytes were completely inhibited by co-incubation with 100 μM gallein, a Gβγ-protein inhibitor (a) and 10 μM U73122, a PLC inhibitor (b), but were partially inhibited by co-incubation with 10 μM DBHQ, an ATPase inhibitor (c). (d) Quantified data showing the percentages of SLIGRL-responsive keratinocytes before and after the incubation of gallein, U73122 or DBHQ. *p < 0.05, **p < 0.01, ***p < 0.001, unpaired t test, n = 3 mice per group. (e) TSLP in cultured media after SLIGRL stimulation was assayed by ELISA. Keratinocytes from Trpv3−/− and Par2−/− mice released less TSLP in response to SLIGRL stimulation. n = 3 mice per group. *p < 0.05, **p < 0.01, two-way ANOVA with Bonferroni post hoc test.

    Techniques Used: Incubation, Cell Culture, Enzyme-linked Immunosorbent Assay

    (a) WT, Trpv3−/− and Par2−/− mice were treated daily with a topical application of MC-903. Scratching numbers were recorded on day 1, 3, 5, and 7. Two-way ANOVA followed by Bonferroni post hoc. n = 6–8 mice per group. (b) Real time RT-PCR showing the relative levels of TRPV3 and PAR2 mRNA in pruritic skin lesions of AD patients and normal control. Unpaired t test. n = 12. (c, d) Relative levels of PAR2 mRNA (c) and TRPV3 mRNA (e) in the ears of MC-903-treated mice on day 5. Two-way ANOVA with Bonferroni post hoc. n = 4–5. Data are presented as mean ± s.e.m. *p < 0.05, **p < 0.01, ***p < 0.001.
    Figure Legend Snippet: (a) WT, Trpv3−/− and Par2−/− mice were treated daily with a topical application of MC-903. Scratching numbers were recorded on day 1, 3, 5, and 7. Two-way ANOVA followed by Bonferroni post hoc. n = 6–8 mice per group. (b) Real time RT-PCR showing the relative levels of TRPV3 and PAR2 mRNA in pruritic skin lesions of AD patients and normal control. Unpaired t test. n = 12. (c, d) Relative levels of PAR2 mRNA (c) and TRPV3 mRNA (e) in the ears of MC-903-treated mice on day 5. Two-way ANOVA with Bonferroni post hoc. n = 4–5. Data are presented as mean ± s.e.m. *p < 0.05, **p < 0.01, ***p < 0.001.

    Techniques Used: Quantitative RT-PCR

    (a-d) Ear appearance of WT mice topically applied with vehicle as a control (a), MC-903 (b), MC-903+74a (c), and MC-903+FSLLRY (d) for 7 days. (e-h) Hematoxylin-eosin staining showing changes in hyperkeratosis and inflammatory infiltration in the ears of corresponding mice in panels a-d, respectively. Scale = 50 μm. (i. j) The scratching numbers (i) and ear thickness increment (j) of mice treated with MC-903, MC-903+74a and MC-903+FSLLRY for 7 days. One-way ANOVA followed by Tukey’s post hoc. n = 6–8 mice per group. (k) Diagram illustrating PAR2-TRPV3 signaling pathway in itch.
    Figure Legend Snippet: (a-d) Ear appearance of WT mice topically applied with vehicle as a control (a), MC-903 (b), MC-903+74a (c), and MC-903+FSLLRY (d) for 7 days. (e-h) Hematoxylin-eosin staining showing changes in hyperkeratosis and inflammatory infiltration in the ears of corresponding mice in panels a-d, respectively. Scale = 50 μm. (i. j) The scratching numbers (i) and ear thickness increment (j) of mice treated with MC-903, MC-903+74a and MC-903+FSLLRY for 7 days. One-way ANOVA followed by Tukey’s post hoc. n = 6–8 mice per group. (k) Diagram illustrating PAR2-TRPV3 signaling pathway in itch.

    Techniques Used: Staining

    immunofluorescence primary antibodies  (Alomone Labs)


    Bioz Verified Symbol Alomone Labs is a verified supplier
    Bioz Manufacturer Symbol Alomone Labs manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 92

    Structured Review

    Alomone Labs immunofluorescence primary antibodies
    Immunofluorescence Primary Antibodies, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/immunofluorescence primary antibodies/product/Alomone Labs
    Average 92 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    immunofluorescence primary antibodies - by Bioz Stars, 2023-02
    92/100 stars

    Images

    immunofluorescence  (Alomone Labs)


    Bioz Verified Symbol Alomone Labs is a verified supplier
    Bioz Manufacturer Symbol Alomone Labs manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 92

    Structured Review

    Alomone Labs immunofluorescence
    Immunofluorescence, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/immunofluorescence/product/Alomone Labs
    Average 92 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    immunofluorescence - by Bioz Stars, 2023-02
    92/100 stars

    Images

    goat anti trpv3  (Alomone Labs)


    Bioz Verified Symbol Alomone Labs is a verified supplier
    Bioz Manufacturer Symbol Alomone Labs manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    Alomone Labs goat anti trpv3
    (a) Acute itch behaviors of <t>Trpv3−/−</t> mice and their WT littermates induced by intradermal injections of SLIGRL (50 μg), trypsin (100 μg), 2fly (10 μg), histamine (200 μg), and BAM 8-22 (150 μg). Unpaired t tests. n = 6–8. (b) WT mice were pre-injected with vehicle (Veh) (8% DMSO), 74a (150 μg, i.d.) or FSLLRY (100 μg, i.d.) 15 min before testing the scratching behaviors elicited by SLIGRL, trypsin, or 2fly. One-way ANOVA followed by Tukey’s post hoc. n = 6-8 mice per group. (c) TRPV3 expression in the skin and DRG of Trpv3+/+ and Trpv3−/− mice as determined by western blot. (d) Double immunofluorescence staining of PAR2 (green) and TRPV3 (red) in mouse keratinocytes. Scale bar, 20 μm. (e) Venn diagram showing the overlapping of PAR2 and TRPV3 in mouse keratinocytes. *p < 0.05, **p < 0.01, ***p < 0.001. Data are presented as mean ± s.e.m.
    Goat Anti Trpv3, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/goat anti trpv3/product/Alomone Labs
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    goat anti trpv3 - by Bioz Stars, 2023-02
    86/100 stars

    Images

    1) Product Images from "PAR2 mediates itch via TRPV3 signaling in keratinocytes"

    Article Title: PAR2 mediates itch via TRPV3 signaling in keratinocytes

    Journal: The Journal of investigative dermatology

    doi: 10.1016/j.jid.2020.01.012

    (a) Acute itch behaviors of Trpv3−/− mice and their WT littermates induced by intradermal injections of SLIGRL (50 μg), trypsin (100 μg), 2fly (10 μg), histamine (200 μg), and BAM 8-22 (150 μg). Unpaired t tests. n = 6–8. (b) WT mice were pre-injected with vehicle (Veh) (8% DMSO), 74a (150 μg, i.d.) or FSLLRY (100 μg, i.d.) 15 min before testing the scratching behaviors elicited by SLIGRL, trypsin, or 2fly. One-way ANOVA followed by Tukey’s post hoc. n = 6-8 mice per group. (c) TRPV3 expression in the skin and DRG of Trpv3+/+ and Trpv3−/− mice as determined by western blot. (d) Double immunofluorescence staining of PAR2 (green) and TRPV3 (red) in mouse keratinocytes. Scale bar, 20 μm. (e) Venn diagram showing the overlapping of PAR2 and TRPV3 in mouse keratinocytes. *p < 0.05, **p < 0.01, ***p < 0.001. Data are presented as mean ± s.e.m.
    Figure Legend Snippet: (a) Acute itch behaviors of Trpv3−/− mice and their WT littermates induced by intradermal injections of SLIGRL (50 μg), trypsin (100 μg), 2fly (10 μg), histamine (200 μg), and BAM 8-22 (150 μg). Unpaired t tests. n = 6–8. (b) WT mice were pre-injected with vehicle (Veh) (8% DMSO), 74a (150 μg, i.d.) or FSLLRY (100 μg, i.d.) 15 min before testing the scratching behaviors elicited by SLIGRL, trypsin, or 2fly. One-way ANOVA followed by Tukey’s post hoc. n = 6-8 mice per group. (c) TRPV3 expression in the skin and DRG of Trpv3+/+ and Trpv3−/− mice as determined by western blot. (d) Double immunofluorescence staining of PAR2 (green) and TRPV3 (red) in mouse keratinocytes. Scale bar, 20 μm. (e) Venn diagram showing the overlapping of PAR2 and TRPV3 in mouse keratinocytes. *p < 0.05, **p < 0.01, ***p < 0.001. Data are presented as mean ± s.e.m.

    Techniques Used: Injection, Expressing, Western Blot, Double Immunofluorescence Staining

    (a) The percentages of responding keratinocytes from WT and Trpv3−/− mice stimulated with histamine (100 μM) and SLIGRL (50 μM). ***p < 0.001, unpaired t tests. n = 3 mice per group. (b) Representative fluorescence images of Fura2 (2 μM)-loaded WT, Trpv3−/− and Par2−/− keratinocytes stimulated with SLIGRL (50 μM). Scale bar, 20 μm. (c) Representative traces showing intracellular Ca2+ responses elicited by SLIGRL (50 μM) in WT mouse keratinocytes. (d, e) The effect of FSLLRY (100 μM) (d) and 74a (100 μM) (e) on SLIGRL-induced Ca2+ responses in WT mouse keratinocytes. (f) The effect of 74a (100 μM) on SLIGKV-induced (100 μM) Ca2+responses in human keratinocytes. (g) Quantified data showing the percentages of SLIGRL-responsive keratinocytes before and after the incubation of FSLLRY or 74a. ***p < 0.001, unpaired t test, n = 3 mice per group. Data are presented as mean ± s.e.m.
    Figure Legend Snippet: (a) The percentages of responding keratinocytes from WT and Trpv3−/− mice stimulated with histamine (100 μM) and SLIGRL (50 μM). ***p < 0.001, unpaired t tests. n = 3 mice per group. (b) Representative fluorescence images of Fura2 (2 μM)-loaded WT, Trpv3−/− and Par2−/− keratinocytes stimulated with SLIGRL (50 μM). Scale bar, 20 μm. (c) Representative traces showing intracellular Ca2+ responses elicited by SLIGRL (50 μM) in WT mouse keratinocytes. (d, e) The effect of FSLLRY (100 μM) (d) and 74a (100 μM) (e) on SLIGRL-induced Ca2+ responses in WT mouse keratinocytes. (f) The effect of 74a (100 μM) on SLIGKV-induced (100 μM) Ca2+responses in human keratinocytes. (g) Quantified data showing the percentages of SLIGRL-responsive keratinocytes before and after the incubation of FSLLRY or 74a. ***p < 0.001, unpaired t test, n = 3 mice per group. Data are presented as mean ± s.e.m.

    Techniques Used: Fluorescence, Incubation

    (a-c) Representative traces showing that Ca2+ transients elicited by SLIGRL (50 μM) in WT mouse keratinocytes were completely inhibited by co-incubation with 100 μM gallein, a Gβγ-protein inhibitor (a) and 10 μM U73122, a PLC inhibitor (b), but were partially inhibited by co-incubation with 10 μM DBHQ, an ATPase inhibitor (c). (d) Quantified data showing the percentages of SLIGRL-responsive keratinocytes before and after the incubation of gallein, U73122 or DBHQ. *p < 0.05, **p < 0.01, ***p < 0.001, unpaired t test, n = 3 mice per group. (e) TSLP in cultured media after SLIGRL stimulation was assayed by ELISA. Keratinocytes from Trpv3−/− and Par2−/− mice released less TSLP in response to SLIGRL stimulation. n = 3 mice per group. *p < 0.05, **p < 0.01, two-way ANOVA with Bonferroni post hoc test.
    Figure Legend Snippet: (a-c) Representative traces showing that Ca2+ transients elicited by SLIGRL (50 μM) in WT mouse keratinocytes were completely inhibited by co-incubation with 100 μM gallein, a Gβγ-protein inhibitor (a) and 10 μM U73122, a PLC inhibitor (b), but were partially inhibited by co-incubation with 10 μM DBHQ, an ATPase inhibitor (c). (d) Quantified data showing the percentages of SLIGRL-responsive keratinocytes before and after the incubation of gallein, U73122 or DBHQ. *p < 0.05, **p < 0.01, ***p < 0.001, unpaired t test, n = 3 mice per group. (e) TSLP in cultured media after SLIGRL stimulation was assayed by ELISA. Keratinocytes from Trpv3−/− and Par2−/− mice released less TSLP in response to SLIGRL stimulation. n = 3 mice per group. *p < 0.05, **p < 0.01, two-way ANOVA with Bonferroni post hoc test.

    Techniques Used: Incubation, Cell Culture, Enzyme-linked Immunosorbent Assay

    (a) WT, Trpv3−/− and Par2−/− mice were treated daily with a topical application of MC-903. Scratching numbers were recorded on day 1, 3, 5, and 7. Two-way ANOVA followed by Bonferroni post hoc. n = 6–8 mice per group. (b) Real time RT-PCR showing the relative levels of TRPV3 and PAR2 mRNA in pruritic skin lesions of AD patients and normal control. Unpaired t test. n = 12. (c, d) Relative levels of PAR2 mRNA (c) and TRPV3 mRNA (e) in the ears of MC-903-treated mice on day 5. Two-way ANOVA with Bonferroni post hoc. n = 4–5. Data are presented as mean ± s.e.m. *p < 0.05, **p < 0.01, ***p < 0.001.
    Figure Legend Snippet: (a) WT, Trpv3−/− and Par2−/− mice were treated daily with a topical application of MC-903. Scratching numbers were recorded on day 1, 3, 5, and 7. Two-way ANOVA followed by Bonferroni post hoc. n = 6–8 mice per group. (b) Real time RT-PCR showing the relative levels of TRPV3 and PAR2 mRNA in pruritic skin lesions of AD patients and normal control. Unpaired t test. n = 12. (c, d) Relative levels of PAR2 mRNA (c) and TRPV3 mRNA (e) in the ears of MC-903-treated mice on day 5. Two-way ANOVA with Bonferroni post hoc. n = 4–5. Data are presented as mean ± s.e.m. *p < 0.05, **p < 0.01, ***p < 0.001.

    Techniques Used: Quantitative RT-PCR

    (a-d) Ear appearance of WT mice topically applied with vehicle as a control (a), MC-903 (b), MC-903+74a (c), and MC-903+FSLLRY (d) for 7 days. (e-h) Hematoxylin-eosin staining showing changes in hyperkeratosis and inflammatory infiltration in the ears of corresponding mice in panels a-d, respectively. Scale = 50 μm. (i. j) The scratching numbers (i) and ear thickness increment (j) of mice treated with MC-903, MC-903+74a and MC-903+FSLLRY for 7 days. One-way ANOVA followed by Tukey’s post hoc. n = 6–8 mice per group. (k) Diagram illustrating PAR2-TRPV3 signaling pathway in itch.
    Figure Legend Snippet: (a-d) Ear appearance of WT mice topically applied with vehicle as a control (a), MC-903 (b), MC-903+74a (c), and MC-903+FSLLRY (d) for 7 days. (e-h) Hematoxylin-eosin staining showing changes in hyperkeratosis and inflammatory infiltration in the ears of corresponding mice in panels a-d, respectively. Scale = 50 μm. (i. j) The scratching numbers (i) and ear thickness increment (j) of mice treated with MC-903, MC-903+74a and MC-903+FSLLRY for 7 days. One-way ANOVA followed by Tukey’s post hoc. n = 6–8 mice per group. (k) Diagram illustrating PAR2-TRPV3 signaling pathway in itch.

    Techniques Used: Staining

    goat anti trpv3  (Alomone Labs)


    Bioz Verified Symbol Alomone Labs is a verified supplier
    Bioz Manufacturer Symbol Alomone Labs manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 92

    Structured Review

    Alomone Labs goat anti trpv3
    (a) Acute itch behaviors of <t>Trpv3−/−</t> mice and their WT littermates induced by intradermal injections of SLIGRL (50 μg), trypsin (100 μg), 2fly (10 μg), histamine (200 μg), and BAM 8-22 (150 μg). Unpaired t tests. n = 6–8. (b) WT mice were pre-injected with vehicle (Veh) (8% DMSO), 74a (150 μg, i.d.) or FSLLRY (100 μg, i.d.) 15 min before testing the scratching behaviors elicited by SLIGRL, trypsin, or 2fly. One-way ANOVA followed by Tukey’s post hoc. n = 6-8 mice per group. (c) TRPV3 expression in the skin and DRG of Trpv3+/+ and Trpv3−/− mice as determined by western blot. (d) Double immunofluorescence staining of PAR2 (green) and TRPV3 (red) in mouse keratinocytes. Scale bar, 20 μm. (e) Venn diagram showing the overlapping of PAR2 and TRPV3 in mouse keratinocytes. *p < 0.05, **p < 0.01, ***p < 0.001. Data are presented as mean ± s.e.m.
    Goat Anti Trpv3, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/goat anti trpv3/product/Alomone Labs
    Average 92 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    goat anti trpv3 - by Bioz Stars, 2023-02
    92/100 stars

    Images

    1) Product Images from "PAR2 mediates itch via TRPV3 signaling in keratinocytes"

    Article Title: PAR2 mediates itch via TRPV3 signaling in keratinocytes

    Journal: The Journal of investigative dermatology

    doi: 10.1016/j.jid.2020.01.012

    (a) Acute itch behaviors of Trpv3−/− mice and their WT littermates induced by intradermal injections of SLIGRL (50 μg), trypsin (100 μg), 2fly (10 μg), histamine (200 μg), and BAM 8-22 (150 μg). Unpaired t tests. n = 6–8. (b) WT mice were pre-injected with vehicle (Veh) (8% DMSO), 74a (150 μg, i.d.) or FSLLRY (100 μg, i.d.) 15 min before testing the scratching behaviors elicited by SLIGRL, trypsin, or 2fly. One-way ANOVA followed by Tukey’s post hoc. n = 6-8 mice per group. (c) TRPV3 expression in the skin and DRG of Trpv3+/+ and Trpv3−/− mice as determined by western blot. (d) Double immunofluorescence staining of PAR2 (green) and TRPV3 (red) in mouse keratinocytes. Scale bar, 20 μm. (e) Venn diagram showing the overlapping of PAR2 and TRPV3 in mouse keratinocytes. *p < 0.05, **p < 0.01, ***p < 0.001. Data are presented as mean ± s.e.m.
    Figure Legend Snippet: (a) Acute itch behaviors of Trpv3−/− mice and their WT littermates induced by intradermal injections of SLIGRL (50 μg), trypsin (100 μg), 2fly (10 μg), histamine (200 μg), and BAM 8-22 (150 μg). Unpaired t tests. n = 6–8. (b) WT mice were pre-injected with vehicle (Veh) (8% DMSO), 74a (150 μg, i.d.) or FSLLRY (100 μg, i.d.) 15 min before testing the scratching behaviors elicited by SLIGRL, trypsin, or 2fly. One-way ANOVA followed by Tukey’s post hoc. n = 6-8 mice per group. (c) TRPV3 expression in the skin and DRG of Trpv3+/+ and Trpv3−/− mice as determined by western blot. (d) Double immunofluorescence staining of PAR2 (green) and TRPV3 (red) in mouse keratinocytes. Scale bar, 20 μm. (e) Venn diagram showing the overlapping of PAR2 and TRPV3 in mouse keratinocytes. *p < 0.05, **p < 0.01, ***p < 0.001. Data are presented as mean ± s.e.m.

    Techniques Used: Injection, Expressing, Western Blot, Double Immunofluorescence Staining

    (a) The percentages of responding keratinocytes from WT and Trpv3−/− mice stimulated with histamine (100 μM) and SLIGRL (50 μM). ***p < 0.001, unpaired t tests. n = 3 mice per group. (b) Representative fluorescence images of Fura2 (2 μM)-loaded WT, Trpv3−/− and Par2−/− keratinocytes stimulated with SLIGRL (50 μM). Scale bar, 20 μm. (c) Representative traces showing intracellular Ca2+ responses elicited by SLIGRL (50 μM) in WT mouse keratinocytes. (d, e) The effect of FSLLRY (100 μM) (d) and 74a (100 μM) (e) on SLIGRL-induced Ca2+ responses in WT mouse keratinocytes. (f) The effect of 74a (100 μM) on SLIGKV-induced (100 μM) Ca2+responses in human keratinocytes. (g) Quantified data showing the percentages of SLIGRL-responsive keratinocytes before and after the incubation of FSLLRY or 74a. ***p < 0.001, unpaired t test, n = 3 mice per group. Data are presented as mean ± s.e.m.
    Figure Legend Snippet: (a) The percentages of responding keratinocytes from WT and Trpv3−/− mice stimulated with histamine (100 μM) and SLIGRL (50 μM). ***p < 0.001, unpaired t tests. n = 3 mice per group. (b) Representative fluorescence images of Fura2 (2 μM)-loaded WT, Trpv3−/− and Par2−/− keratinocytes stimulated with SLIGRL (50 μM). Scale bar, 20 μm. (c) Representative traces showing intracellular Ca2+ responses elicited by SLIGRL (50 μM) in WT mouse keratinocytes. (d, e) The effect of FSLLRY (100 μM) (d) and 74a (100 μM) (e) on SLIGRL-induced Ca2+ responses in WT mouse keratinocytes. (f) The effect of 74a (100 μM) on SLIGKV-induced (100 μM) Ca2+responses in human keratinocytes. (g) Quantified data showing the percentages of SLIGRL-responsive keratinocytes before and after the incubation of FSLLRY or 74a. ***p < 0.001, unpaired t test, n = 3 mice per group. Data are presented as mean ± s.e.m.

    Techniques Used: Fluorescence, Incubation

    (a-c) Representative traces showing that Ca2+ transients elicited by SLIGRL (50 μM) in WT mouse keratinocytes were completely inhibited by co-incubation with 100 μM gallein, a Gβγ-protein inhibitor (a) and 10 μM U73122, a PLC inhibitor (b), but were partially inhibited by co-incubation with 10 μM DBHQ, an ATPase inhibitor (c). (d) Quantified data showing the percentages of SLIGRL-responsive keratinocytes before and after the incubation of gallein, U73122 or DBHQ. *p < 0.05, **p < 0.01, ***p < 0.001, unpaired t test, n = 3 mice per group. (e) TSLP in cultured media after SLIGRL stimulation was assayed by ELISA. Keratinocytes from Trpv3−/− and Par2−/− mice released less TSLP in response to SLIGRL stimulation. n = 3 mice per group. *p < 0.05, **p < 0.01, two-way ANOVA with Bonferroni post hoc test.
    Figure Legend Snippet: (a-c) Representative traces showing that Ca2+ transients elicited by SLIGRL (50 μM) in WT mouse keratinocytes were completely inhibited by co-incubation with 100 μM gallein, a Gβγ-protein inhibitor (a) and 10 μM U73122, a PLC inhibitor (b), but were partially inhibited by co-incubation with 10 μM DBHQ, an ATPase inhibitor (c). (d) Quantified data showing the percentages of SLIGRL-responsive keratinocytes before and after the incubation of gallein, U73122 or DBHQ. *p < 0.05, **p < 0.01, ***p < 0.001, unpaired t test, n = 3 mice per group. (e) TSLP in cultured media after SLIGRL stimulation was assayed by ELISA. Keratinocytes from Trpv3−/− and Par2−/− mice released less TSLP in response to SLIGRL stimulation. n = 3 mice per group. *p < 0.05, **p < 0.01, two-way ANOVA with Bonferroni post hoc test.

    Techniques Used: Incubation, Cell Culture, Enzyme-linked Immunosorbent Assay

    (a) WT, Trpv3−/− and Par2−/− mice were treated daily with a topical application of MC-903. Scratching numbers were recorded on day 1, 3, 5, and 7. Two-way ANOVA followed by Bonferroni post hoc. n = 6–8 mice per group. (b) Real time RT-PCR showing the relative levels of TRPV3 and PAR2 mRNA in pruritic skin lesions of AD patients and normal control. Unpaired t test. n = 12. (c, d) Relative levels of PAR2 mRNA (c) and TRPV3 mRNA (e) in the ears of MC-903-treated mice on day 5. Two-way ANOVA with Bonferroni post hoc. n = 4–5. Data are presented as mean ± s.e.m. *p < 0.05, **p < 0.01, ***p < 0.001.
    Figure Legend Snippet: (a) WT, Trpv3−/− and Par2−/− mice were treated daily with a topical application of MC-903. Scratching numbers were recorded on day 1, 3, 5, and 7. Two-way ANOVA followed by Bonferroni post hoc. n = 6–8 mice per group. (b) Real time RT-PCR showing the relative levels of TRPV3 and PAR2 mRNA in pruritic skin lesions of AD patients and normal control. Unpaired t test. n = 12. (c, d) Relative levels of PAR2 mRNA (c) and TRPV3 mRNA (e) in the ears of MC-903-treated mice on day 5. Two-way ANOVA with Bonferroni post hoc. n = 4–5. Data are presented as mean ± s.e.m. *p < 0.05, **p < 0.01, ***p < 0.001.

    Techniques Used: Quantitative RT-PCR

    (a-d) Ear appearance of WT mice topically applied with vehicle as a control (a), MC-903 (b), MC-903+74a (c), and MC-903+FSLLRY (d) for 7 days. (e-h) Hematoxylin-eosin staining showing changes in hyperkeratosis and inflammatory infiltration in the ears of corresponding mice in panels a-d, respectively. Scale = 50 μm. (i. j) The scratching numbers (i) and ear thickness increment (j) of mice treated with MC-903, MC-903+74a and MC-903+FSLLRY for 7 days. One-way ANOVA followed by Tukey’s post hoc. n = 6–8 mice per group. (k) Diagram illustrating PAR2-TRPV3 signaling pathway in itch.
    Figure Legend Snippet: (a-d) Ear appearance of WT mice topically applied with vehicle as a control (a), MC-903 (b), MC-903+74a (c), and MC-903+FSLLRY (d) for 7 days. (e-h) Hematoxylin-eosin staining showing changes in hyperkeratosis and inflammatory infiltration in the ears of corresponding mice in panels a-d, respectively. Scale = 50 μm. (i. j) The scratching numbers (i) and ear thickness increment (j) of mice treated with MC-903, MC-903+74a and MC-903+FSLLRY for 7 days. One-way ANOVA followed by Tukey’s post hoc. n = 6–8 mice per group. (k) Diagram illustrating PAR2-TRPV3 signaling pathway in itch.

    Techniques Used: Staining

    anti trpv3 antibody  (Alomone Labs)


    Bioz Verified Symbol Alomone Labs is a verified supplier
    Bioz Manufacturer Symbol Alomone Labs manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Alomone Labs anti trpv3 antibody
    (a) Acute itch behaviors of <t>Trpv3−/−</t> mice and their WT littermates induced by intradermal injections of SLIGRL (50 μg), trypsin (100 μg), 2fly (10 μg), histamine (200 μg), and BAM 8-22 (150 μg). Unpaired t tests. n = 6–8. (b) WT mice were pre-injected with vehicle (Veh) (8% DMSO), 74a (150 μg, i.d.) or FSLLRY (100 μg, i.d.) 15 min before testing the scratching behaviors elicited by SLIGRL, trypsin, or 2fly. One-way ANOVA followed by Tukey’s post hoc. n = 6-8 mice per group. (c) TRPV3 expression in the skin and DRG of Trpv3+/+ and Trpv3−/− mice as determined by western blot. (d) Double immunofluorescence staining of PAR2 (green) and TRPV3 (red) in mouse keratinocytes. Scale bar, 20 μm. (e) Venn diagram showing the overlapping of PAR2 and TRPV3 in mouse keratinocytes. *p < 0.05, **p < 0.01, ***p < 0.001. Data are presented as mean ± s.e.m.
    Anti Trpv3 Antibody, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti trpv3 antibody/product/Alomone Labs
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti trpv3 antibody - by Bioz Stars, 2023-02
    93/100 stars

    Images

    1) Product Images from "PAR2 mediates itch via TRPV3 signaling in keratinocytes"

    Article Title: PAR2 mediates itch via TRPV3 signaling in keratinocytes

    Journal: The Journal of investigative dermatology

    doi: 10.1016/j.jid.2020.01.012

    (a) Acute itch behaviors of Trpv3−/− mice and their WT littermates induced by intradermal injections of SLIGRL (50 μg), trypsin (100 μg), 2fly (10 μg), histamine (200 μg), and BAM 8-22 (150 μg). Unpaired t tests. n = 6–8. (b) WT mice were pre-injected with vehicle (Veh) (8% DMSO), 74a (150 μg, i.d.) or FSLLRY (100 μg, i.d.) 15 min before testing the scratching behaviors elicited by SLIGRL, trypsin, or 2fly. One-way ANOVA followed by Tukey’s post hoc. n = 6-8 mice per group. (c) TRPV3 expression in the skin and DRG of Trpv3+/+ and Trpv3−/− mice as determined by western blot. (d) Double immunofluorescence staining of PAR2 (green) and TRPV3 (red) in mouse keratinocytes. Scale bar, 20 μm. (e) Venn diagram showing the overlapping of PAR2 and TRPV3 in mouse keratinocytes. *p < 0.05, **p < 0.01, ***p < 0.001. Data are presented as mean ± s.e.m.
    Figure Legend Snippet: (a) Acute itch behaviors of Trpv3−/− mice and their WT littermates induced by intradermal injections of SLIGRL (50 μg), trypsin (100 μg), 2fly (10 μg), histamine (200 μg), and BAM 8-22 (150 μg). Unpaired t tests. n = 6–8. (b) WT mice were pre-injected with vehicle (Veh) (8% DMSO), 74a (150 μg, i.d.) or FSLLRY (100 μg, i.d.) 15 min before testing the scratching behaviors elicited by SLIGRL, trypsin, or 2fly. One-way ANOVA followed by Tukey’s post hoc. n = 6-8 mice per group. (c) TRPV3 expression in the skin and DRG of Trpv3+/+ and Trpv3−/− mice as determined by western blot. (d) Double immunofluorescence staining of PAR2 (green) and TRPV3 (red) in mouse keratinocytes. Scale bar, 20 μm. (e) Venn diagram showing the overlapping of PAR2 and TRPV3 in mouse keratinocytes. *p < 0.05, **p < 0.01, ***p < 0.001. Data are presented as mean ± s.e.m.

    Techniques Used: Injection, Expressing, Western Blot, Double Immunofluorescence Staining

    (a) The percentages of responding keratinocytes from WT and Trpv3−/− mice stimulated with histamine (100 μM) and SLIGRL (50 μM). ***p < 0.001, unpaired t tests. n = 3 mice per group. (b) Representative fluorescence images of Fura2 (2 μM)-loaded WT, Trpv3−/− and Par2−/− keratinocytes stimulated with SLIGRL (50 μM). Scale bar, 20 μm. (c) Representative traces showing intracellular Ca2+ responses elicited by SLIGRL (50 μM) in WT mouse keratinocytes. (d, e) The effect of FSLLRY (100 μM) (d) and 74a (100 μM) (e) on SLIGRL-induced Ca2+ responses in WT mouse keratinocytes. (f) The effect of 74a (100 μM) on SLIGKV-induced (100 μM) Ca2+responses in human keratinocytes. (g) Quantified data showing the percentages of SLIGRL-responsive keratinocytes before and after the incubation of FSLLRY or 74a. ***p < 0.001, unpaired t test, n = 3 mice per group. Data are presented as mean ± s.e.m.
    Figure Legend Snippet: (a) The percentages of responding keratinocytes from WT and Trpv3−/− mice stimulated with histamine (100 μM) and SLIGRL (50 μM). ***p < 0.001, unpaired t tests. n = 3 mice per group. (b) Representative fluorescence images of Fura2 (2 μM)-loaded WT, Trpv3−/− and Par2−/− keratinocytes stimulated with SLIGRL (50 μM). Scale bar, 20 μm. (c) Representative traces showing intracellular Ca2+ responses elicited by SLIGRL (50 μM) in WT mouse keratinocytes. (d, e) The effect of FSLLRY (100 μM) (d) and 74a (100 μM) (e) on SLIGRL-induced Ca2+ responses in WT mouse keratinocytes. (f) The effect of 74a (100 μM) on SLIGKV-induced (100 μM) Ca2+responses in human keratinocytes. (g) Quantified data showing the percentages of SLIGRL-responsive keratinocytes before and after the incubation of FSLLRY or 74a. ***p < 0.001, unpaired t test, n = 3 mice per group. Data are presented as mean ± s.e.m.

    Techniques Used: Fluorescence, Incubation

    (a-c) Representative traces showing that Ca2+ transients elicited by SLIGRL (50 μM) in WT mouse keratinocytes were completely inhibited by co-incubation with 100 μM gallein, a Gβγ-protein inhibitor (a) and 10 μM U73122, a PLC inhibitor (b), but were partially inhibited by co-incubation with 10 μM DBHQ, an ATPase inhibitor (c). (d) Quantified data showing the percentages of SLIGRL-responsive keratinocytes before and after the incubation of gallein, U73122 or DBHQ. *p < 0.05, **p < 0.01, ***p < 0.001, unpaired t test, n = 3 mice per group. (e) TSLP in cultured media after SLIGRL stimulation was assayed by ELISA. Keratinocytes from Trpv3−/− and Par2−/− mice released less TSLP in response to SLIGRL stimulation. n = 3 mice per group. *p < 0.05, **p < 0.01, two-way ANOVA with Bonferroni post hoc test.
    Figure Legend Snippet: (a-c) Representative traces showing that Ca2+ transients elicited by SLIGRL (50 μM) in WT mouse keratinocytes were completely inhibited by co-incubation with 100 μM gallein, a Gβγ-protein inhibitor (a) and 10 μM U73122, a PLC inhibitor (b), but were partially inhibited by co-incubation with 10 μM DBHQ, an ATPase inhibitor (c). (d) Quantified data showing the percentages of SLIGRL-responsive keratinocytes before and after the incubation of gallein, U73122 or DBHQ. *p < 0.05, **p < 0.01, ***p < 0.001, unpaired t test, n = 3 mice per group. (e) TSLP in cultured media after SLIGRL stimulation was assayed by ELISA. Keratinocytes from Trpv3−/− and Par2−/− mice released less TSLP in response to SLIGRL stimulation. n = 3 mice per group. *p < 0.05, **p < 0.01, two-way ANOVA with Bonferroni post hoc test.

    Techniques Used: Incubation, Cell Culture, Enzyme-linked Immunosorbent Assay

    (a) WT, Trpv3−/− and Par2−/− mice were treated daily with a topical application of MC-903. Scratching numbers were recorded on day 1, 3, 5, and 7. Two-way ANOVA followed by Bonferroni post hoc. n = 6–8 mice per group. (b) Real time RT-PCR showing the relative levels of TRPV3 and PAR2 mRNA in pruritic skin lesions of AD patients and normal control. Unpaired t test. n = 12. (c, d) Relative levels of PAR2 mRNA (c) and TRPV3 mRNA (e) in the ears of MC-903-treated mice on day 5. Two-way ANOVA with Bonferroni post hoc. n = 4–5. Data are presented as mean ± s.e.m. *p < 0.05, **p < 0.01, ***p < 0.001.
    Figure Legend Snippet: (a) WT, Trpv3−/− and Par2−/− mice were treated daily with a topical application of MC-903. Scratching numbers were recorded on day 1, 3, 5, and 7. Two-way ANOVA followed by Bonferroni post hoc. n = 6–8 mice per group. (b) Real time RT-PCR showing the relative levels of TRPV3 and PAR2 mRNA in pruritic skin lesions of AD patients and normal control. Unpaired t test. n = 12. (c, d) Relative levels of PAR2 mRNA (c) and TRPV3 mRNA (e) in the ears of MC-903-treated mice on day 5. Two-way ANOVA with Bonferroni post hoc. n = 4–5. Data are presented as mean ± s.e.m. *p < 0.05, **p < 0.01, ***p < 0.001.

    Techniques Used: Quantitative RT-PCR

    (a-d) Ear appearance of WT mice topically applied with vehicle as a control (a), MC-903 (b), MC-903+74a (c), and MC-903+FSLLRY (d) for 7 days. (e-h) Hematoxylin-eosin staining showing changes in hyperkeratosis and inflammatory infiltration in the ears of corresponding mice in panels a-d, respectively. Scale = 50 μm. (i. j) The scratching numbers (i) and ear thickness increment (j) of mice treated with MC-903, MC-903+74a and MC-903+FSLLRY for 7 days. One-way ANOVA followed by Tukey’s post hoc. n = 6–8 mice per group. (k) Diagram illustrating PAR2-TRPV3 signaling pathway in itch.
    Figure Legend Snippet: (a-d) Ear appearance of WT mice topically applied with vehicle as a control (a), MC-903 (b), MC-903+74a (c), and MC-903+FSLLRY (d) for 7 days. (e-h) Hematoxylin-eosin staining showing changes in hyperkeratosis and inflammatory infiltration in the ears of corresponding mice in panels a-d, respectively. Scale = 50 μm. (i. j) The scratching numbers (i) and ear thickness increment (j) of mice treated with MC-903, MC-903+74a and MC-903+FSLLRY for 7 days. One-way ANOVA followed by Tukey’s post hoc. n = 6–8 mice per group. (k) Diagram illustrating PAR2-TRPV3 signaling pathway in itch.

    Techniques Used: Staining

    anti trpv3 primary antibody  (Alomone Labs)


    Bioz Verified Symbol Alomone Labs is a verified supplier
    Bioz Manufacturer Symbol Alomone Labs manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Alomone Labs anti trpv3 primary antibody
    Anti Trpv3 Primary Antibody, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti trpv3 primary antibody/product/Alomone Labs
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti trpv3 primary antibody - by Bioz Stars, 2023-02
    93/100 stars

    Images

    anti trpv3  (Alomone Labs)


    Bioz Verified Symbol Alomone Labs is a verified supplier
    Bioz Manufacturer Symbol Alomone Labs manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Alomone Labs anti trpv3
    Anti Trpv3, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti trpv3/product/Alomone Labs
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti trpv3 - by Bioz Stars, 2023-02
    93/100 stars

    Images

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93
    Alomone Labs cav1 2
    Cav1 2, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cav1 2/product/Alomone Labs
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    cav1 2 - by Bioz Stars, 2023-02
    93/100 stars
      Buy from Supplier

    92
    Alomone Labs immunofluorescence
    Immunofluorescence, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/immunofluorescence/product/Alomone Labs
    Average 92 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    immunofluorescence - by Bioz Stars, 2023-02
    92/100 stars
      Buy from Supplier

    93
    Alomone Labs anti trpv3 antibody
    (a) Acute itch behaviors of <t>Trpv3−/−</t> mice and their WT littermates induced by intradermal injections of SLIGRL (50 μg), trypsin (100 μg), 2fly (10 μg), histamine (200 μg), and BAM 8-22 (150 μg). Unpaired t tests. n = 6–8. (b) WT mice were pre-injected with vehicle (Veh) (8% DMSO), 74a (150 μg, i.d.) or FSLLRY (100 μg, i.d.) 15 min before testing the scratching behaviors elicited by SLIGRL, trypsin, or 2fly. One-way ANOVA followed by Tukey’s post hoc. n = 6-8 mice per group. (c) TRPV3 expression in the skin and DRG of Trpv3+/+ and Trpv3−/− mice as determined by western blot. (d) Double immunofluorescence staining of PAR2 (green) and TRPV3 (red) in mouse keratinocytes. Scale bar, 20 μm. (e) Venn diagram showing the overlapping of PAR2 and TRPV3 in mouse keratinocytes. *p < 0.05, **p < 0.01, ***p < 0.001. Data are presented as mean ± s.e.m.
    Anti Trpv3 Antibody, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti trpv3 antibody/product/Alomone Labs
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti trpv3 antibody - by Bioz Stars, 2023-02
    93/100 stars
      Buy from Supplier

    92
    Alomone Labs immunofluorescence primary antibodies
    (a) Acute itch behaviors of <t>Trpv3−/−</t> mice and their WT littermates induced by intradermal injections of SLIGRL (50 μg), trypsin (100 μg), 2fly (10 μg), histamine (200 μg), and BAM 8-22 (150 μg). Unpaired t tests. n = 6–8. (b) WT mice were pre-injected with vehicle (Veh) (8% DMSO), 74a (150 μg, i.d.) or FSLLRY (100 μg, i.d.) 15 min before testing the scratching behaviors elicited by SLIGRL, trypsin, or 2fly. One-way ANOVA followed by Tukey’s post hoc. n = 6-8 mice per group. (c) TRPV3 expression in the skin and DRG of Trpv3+/+ and Trpv3−/− mice as determined by western blot. (d) Double immunofluorescence staining of PAR2 (green) and TRPV3 (red) in mouse keratinocytes. Scale bar, 20 μm. (e) Venn diagram showing the overlapping of PAR2 and TRPV3 in mouse keratinocytes. *p < 0.05, **p < 0.01, ***p < 0.001. Data are presented as mean ± s.e.m.
    Immunofluorescence Primary Antibodies, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/immunofluorescence primary antibodies/product/Alomone Labs
    Average 92 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    immunofluorescence primary antibodies - by Bioz Stars, 2023-02
    92/100 stars
      Buy from Supplier

    86
    Alomone Labs goat anti trpv3
    (a) Acute itch behaviors of <t>Trpv3−/−</t> mice and their WT littermates induced by intradermal injections of SLIGRL (50 μg), trypsin (100 μg), 2fly (10 μg), histamine (200 μg), and BAM 8-22 (150 μg). Unpaired t tests. n = 6–8. (b) WT mice were pre-injected with vehicle (Veh) (8% DMSO), 74a (150 μg, i.d.) or FSLLRY (100 μg, i.d.) 15 min before testing the scratching behaviors elicited by SLIGRL, trypsin, or 2fly. One-way ANOVA followed by Tukey’s post hoc. n = 6-8 mice per group. (c) TRPV3 expression in the skin and DRG of Trpv3+/+ and Trpv3−/− mice as determined by western blot. (d) Double immunofluorescence staining of PAR2 (green) and TRPV3 (red) in mouse keratinocytes. Scale bar, 20 μm. (e) Venn diagram showing the overlapping of PAR2 and TRPV3 in mouse keratinocytes. *p < 0.05, **p < 0.01, ***p < 0.001. Data are presented as mean ± s.e.m.
    Goat Anti Trpv3, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/goat anti trpv3/product/Alomone Labs
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    goat anti trpv3 - by Bioz Stars, 2023-02
    86/100 stars
      Buy from Supplier

    93
    Alomone Labs anti trpv3 primary antibody
    (a) Acute itch behaviors of <t>Trpv3−/−</t> mice and their WT littermates induced by intradermal injections of SLIGRL (50 μg), trypsin (100 μg), 2fly (10 μg), histamine (200 μg), and BAM 8-22 (150 μg). Unpaired t tests. n = 6–8. (b) WT mice were pre-injected with vehicle (Veh) (8% DMSO), 74a (150 μg, i.d.) or FSLLRY (100 μg, i.d.) 15 min before testing the scratching behaviors elicited by SLIGRL, trypsin, or 2fly. One-way ANOVA followed by Tukey’s post hoc. n = 6-8 mice per group. (c) TRPV3 expression in the skin and DRG of Trpv3+/+ and Trpv3−/− mice as determined by western blot. (d) Double immunofluorescence staining of PAR2 (green) and TRPV3 (red) in mouse keratinocytes. Scale bar, 20 μm. (e) Venn diagram showing the overlapping of PAR2 and TRPV3 in mouse keratinocytes. *p < 0.05, **p < 0.01, ***p < 0.001. Data are presented as mean ± s.e.m.
    Anti Trpv3 Primary Antibody, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti trpv3 primary antibody/product/Alomone Labs
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti trpv3 primary antibody - by Bioz Stars, 2023-02
    93/100 stars
      Buy from Supplier

    93
    Alomone Labs anti trpv3
    (a) Acute itch behaviors of <t>Trpv3−/−</t> mice and their WT littermates induced by intradermal injections of SLIGRL (50 μg), trypsin (100 μg), 2fly (10 μg), histamine (200 μg), and BAM 8-22 (150 μg). Unpaired t tests. n = 6–8. (b) WT mice were pre-injected with vehicle (Veh) (8% DMSO), 74a (150 μg, i.d.) or FSLLRY (100 μg, i.d.) 15 min before testing the scratching behaviors elicited by SLIGRL, trypsin, or 2fly. One-way ANOVA followed by Tukey’s post hoc. n = 6-8 mice per group. (c) TRPV3 expression in the skin and DRG of Trpv3+/+ and Trpv3−/− mice as determined by western blot. (d) Double immunofluorescence staining of PAR2 (green) and TRPV3 (red) in mouse keratinocytes. Scale bar, 20 μm. (e) Venn diagram showing the overlapping of PAR2 and TRPV3 in mouse keratinocytes. *p < 0.05, **p < 0.01, ***p < 0.001. Data are presented as mean ± s.e.m.
    Anti Trpv3, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti trpv3/product/Alomone Labs
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti trpv3 - by Bioz Stars, 2023-02
    93/100 stars
      Buy from Supplier

    Image Search Results


    (a) Acute itch behaviors of Trpv3−/− mice and their WT littermates induced by intradermal injections of SLIGRL (50 μg), trypsin (100 μg), 2fly (10 μg), histamine (200 μg), and BAM 8-22 (150 μg). Unpaired t tests. n = 6–8. (b) WT mice were pre-injected with vehicle (Veh) (8% DMSO), 74a (150 μg, i.d.) or FSLLRY (100 μg, i.d.) 15 min before testing the scratching behaviors elicited by SLIGRL, trypsin, or 2fly. One-way ANOVA followed by Tukey’s post hoc. n = 6-8 mice per group. (c) TRPV3 expression in the skin and DRG of Trpv3+/+ and Trpv3−/− mice as determined by western blot. (d) Double immunofluorescence staining of PAR2 (green) and TRPV3 (red) in mouse keratinocytes. Scale bar, 20 μm. (e) Venn diagram showing the overlapping of PAR2 and TRPV3 in mouse keratinocytes. *p < 0.05, **p < 0.01, ***p < 0.001. Data are presented as mean ± s.e.m.

    Journal: The Journal of investigative dermatology

    Article Title: PAR2 mediates itch via TRPV3 signaling in keratinocytes

    doi: 10.1016/j.jid.2020.01.012

    Figure Lengend Snippet: (a) Acute itch behaviors of Trpv3−/− mice and their WT littermates induced by intradermal injections of SLIGRL (50 μg), trypsin (100 μg), 2fly (10 μg), histamine (200 μg), and BAM 8-22 (150 μg). Unpaired t tests. n = 6–8. (b) WT mice were pre-injected with vehicle (Veh) (8% DMSO), 74a (150 μg, i.d.) or FSLLRY (100 μg, i.d.) 15 min before testing the scratching behaviors elicited by SLIGRL, trypsin, or 2fly. One-way ANOVA followed by Tukey’s post hoc. n = 6-8 mice per group. (c) TRPV3 expression in the skin and DRG of Trpv3+/+ and Trpv3−/− mice as determined by western blot. (d) Double immunofluorescence staining of PAR2 (green) and TRPV3 (red) in mouse keratinocytes. Scale bar, 20 μm. (e) Venn diagram showing the overlapping of PAR2 and TRPV3 in mouse keratinocytes. *p < 0.05, **p < 0.01, ***p < 0.001. Data are presented as mean ± s.e.m.

    Article Snippet: Immunofluorescence Primary antibodies used for immunofluorescence of cultured primary keratinocytes were: anti-TRPV3 antibody (Alomone Labs, 1:300) and anti-PAR2 antibody (Santa Cruz, 1:100).

    Techniques: Injection, Expressing, Western Blot, Double Immunofluorescence Staining

    (a) The percentages of responding keratinocytes from WT and Trpv3−/− mice stimulated with histamine (100 μM) and SLIGRL (50 μM). ***p < 0.001, unpaired t tests. n = 3 mice per group. (b) Representative fluorescence images of Fura2 (2 μM)-loaded WT, Trpv3−/− and Par2−/− keratinocytes stimulated with SLIGRL (50 μM). Scale bar, 20 μm. (c) Representative traces showing intracellular Ca2+ responses elicited by SLIGRL (50 μM) in WT mouse keratinocytes. (d, e) The effect of FSLLRY (100 μM) (d) and 74a (100 μM) (e) on SLIGRL-induced Ca2+ responses in WT mouse keratinocytes. (f) The effect of 74a (100 μM) on SLIGKV-induced (100 μM) Ca2+responses in human keratinocytes. (g) Quantified data showing the percentages of SLIGRL-responsive keratinocytes before and after the incubation of FSLLRY or 74a. ***p < 0.001, unpaired t test, n = 3 mice per group. Data are presented as mean ± s.e.m.

    Journal: The Journal of investigative dermatology

    Article Title: PAR2 mediates itch via TRPV3 signaling in keratinocytes

    doi: 10.1016/j.jid.2020.01.012

    Figure Lengend Snippet: (a) The percentages of responding keratinocytes from WT and Trpv3−/− mice stimulated with histamine (100 μM) and SLIGRL (50 μM). ***p < 0.001, unpaired t tests. n = 3 mice per group. (b) Representative fluorescence images of Fura2 (2 μM)-loaded WT, Trpv3−/− and Par2−/− keratinocytes stimulated with SLIGRL (50 μM). Scale bar, 20 μm. (c) Representative traces showing intracellular Ca2+ responses elicited by SLIGRL (50 μM) in WT mouse keratinocytes. (d, e) The effect of FSLLRY (100 μM) (d) and 74a (100 μM) (e) on SLIGRL-induced Ca2+ responses in WT mouse keratinocytes. (f) The effect of 74a (100 μM) on SLIGKV-induced (100 μM) Ca2+responses in human keratinocytes. (g) Quantified data showing the percentages of SLIGRL-responsive keratinocytes before and after the incubation of FSLLRY or 74a. ***p < 0.001, unpaired t test, n = 3 mice per group. Data are presented as mean ± s.e.m.

    Article Snippet: Immunofluorescence Primary antibodies used for immunofluorescence of cultured primary keratinocytes were: anti-TRPV3 antibody (Alomone Labs, 1:300) and anti-PAR2 antibody (Santa Cruz, 1:100).

    Techniques: Fluorescence, Incubation

    (a-c) Representative traces showing that Ca2+ transients elicited by SLIGRL (50 μM) in WT mouse keratinocytes were completely inhibited by co-incubation with 100 μM gallein, a Gβγ-protein inhibitor (a) and 10 μM U73122, a PLC inhibitor (b), but were partially inhibited by co-incubation with 10 μM DBHQ, an ATPase inhibitor (c). (d) Quantified data showing the percentages of SLIGRL-responsive keratinocytes before and after the incubation of gallein, U73122 or DBHQ. *p < 0.05, **p < 0.01, ***p < 0.001, unpaired t test, n = 3 mice per group. (e) TSLP in cultured media after SLIGRL stimulation was assayed by ELISA. Keratinocytes from Trpv3−/− and Par2−/− mice released less TSLP in response to SLIGRL stimulation. n = 3 mice per group. *p < 0.05, **p < 0.01, two-way ANOVA with Bonferroni post hoc test.

    Journal: The Journal of investigative dermatology

    Article Title: PAR2 mediates itch via TRPV3 signaling in keratinocytes

    doi: 10.1016/j.jid.2020.01.012

    Figure Lengend Snippet: (a-c) Representative traces showing that Ca2+ transients elicited by SLIGRL (50 μM) in WT mouse keratinocytes were completely inhibited by co-incubation with 100 μM gallein, a Gβγ-protein inhibitor (a) and 10 μM U73122, a PLC inhibitor (b), but were partially inhibited by co-incubation with 10 μM DBHQ, an ATPase inhibitor (c). (d) Quantified data showing the percentages of SLIGRL-responsive keratinocytes before and after the incubation of gallein, U73122 or DBHQ. *p < 0.05, **p < 0.01, ***p < 0.001, unpaired t test, n = 3 mice per group. (e) TSLP in cultured media after SLIGRL stimulation was assayed by ELISA. Keratinocytes from Trpv3−/− and Par2−/− mice released less TSLP in response to SLIGRL stimulation. n = 3 mice per group. *p < 0.05, **p < 0.01, two-way ANOVA with Bonferroni post hoc test.

    Article Snippet: Immunofluorescence Primary antibodies used for immunofluorescence of cultured primary keratinocytes were: anti-TRPV3 antibody (Alomone Labs, 1:300) and anti-PAR2 antibody (Santa Cruz, 1:100).

    Techniques: Incubation, Cell Culture, Enzyme-linked Immunosorbent Assay

    (a) WT, Trpv3−/− and Par2−/− mice were treated daily with a topical application of MC-903. Scratching numbers were recorded on day 1, 3, 5, and 7. Two-way ANOVA followed by Bonferroni post hoc. n = 6–8 mice per group. (b) Real time RT-PCR showing the relative levels of TRPV3 and PAR2 mRNA in pruritic skin lesions of AD patients and normal control. Unpaired t test. n = 12. (c, d) Relative levels of PAR2 mRNA (c) and TRPV3 mRNA (e) in the ears of MC-903-treated mice on day 5. Two-way ANOVA with Bonferroni post hoc. n = 4–5. Data are presented as mean ± s.e.m. *p < 0.05, **p < 0.01, ***p < 0.001.

    Journal: The Journal of investigative dermatology

    Article Title: PAR2 mediates itch via TRPV3 signaling in keratinocytes

    doi: 10.1016/j.jid.2020.01.012

    Figure Lengend Snippet: (a) WT, Trpv3−/− and Par2−/− mice were treated daily with a topical application of MC-903. Scratching numbers were recorded on day 1, 3, 5, and 7. Two-way ANOVA followed by Bonferroni post hoc. n = 6–8 mice per group. (b) Real time RT-PCR showing the relative levels of TRPV3 and PAR2 mRNA in pruritic skin lesions of AD patients and normal control. Unpaired t test. n = 12. (c, d) Relative levels of PAR2 mRNA (c) and TRPV3 mRNA (e) in the ears of MC-903-treated mice on day 5. Two-way ANOVA with Bonferroni post hoc. n = 4–5. Data are presented as mean ± s.e.m. *p < 0.05, **p < 0.01, ***p < 0.001.

    Article Snippet: Immunofluorescence Primary antibodies used for immunofluorescence of cultured primary keratinocytes were: anti-TRPV3 antibody (Alomone Labs, 1:300) and anti-PAR2 antibody (Santa Cruz, 1:100).

    Techniques: Quantitative RT-PCR

    (a-d) Ear appearance of WT mice topically applied with vehicle as a control (a), MC-903 (b), MC-903+74a (c), and MC-903+FSLLRY (d) for 7 days. (e-h) Hematoxylin-eosin staining showing changes in hyperkeratosis and inflammatory infiltration in the ears of corresponding mice in panels a-d, respectively. Scale = 50 μm. (i. j) The scratching numbers (i) and ear thickness increment (j) of mice treated with MC-903, MC-903+74a and MC-903+FSLLRY for 7 days. One-way ANOVA followed by Tukey’s post hoc. n = 6–8 mice per group. (k) Diagram illustrating PAR2-TRPV3 signaling pathway in itch.

    Journal: The Journal of investigative dermatology

    Article Title: PAR2 mediates itch via TRPV3 signaling in keratinocytes

    doi: 10.1016/j.jid.2020.01.012

    Figure Lengend Snippet: (a-d) Ear appearance of WT mice topically applied with vehicle as a control (a), MC-903 (b), MC-903+74a (c), and MC-903+FSLLRY (d) for 7 days. (e-h) Hematoxylin-eosin staining showing changes in hyperkeratosis and inflammatory infiltration in the ears of corresponding mice in panels a-d, respectively. Scale = 50 μm. (i. j) The scratching numbers (i) and ear thickness increment (j) of mice treated with MC-903, MC-903+74a and MC-903+FSLLRY for 7 days. One-way ANOVA followed by Tukey’s post hoc. n = 6–8 mice per group. (k) Diagram illustrating PAR2-TRPV3 signaling pathway in itch.

    Article Snippet: Immunofluorescence Primary antibodies used for immunofluorescence of cultured primary keratinocytes were: anti-TRPV3 antibody (Alomone Labs, 1:300) and anti-PAR2 antibody (Santa Cruz, 1:100).

    Techniques: Staining

    (a) Acute itch behaviors of Trpv3−/− mice and their WT littermates induced by intradermal injections of SLIGRL (50 μg), trypsin (100 μg), 2fly (10 μg), histamine (200 μg), and BAM 8-22 (150 μg). Unpaired t tests. n = 6–8. (b) WT mice were pre-injected with vehicle (Veh) (8% DMSO), 74a (150 μg, i.d.) or FSLLRY (100 μg, i.d.) 15 min before testing the scratching behaviors elicited by SLIGRL, trypsin, or 2fly. One-way ANOVA followed by Tukey’s post hoc. n = 6-8 mice per group. (c) TRPV3 expression in the skin and DRG of Trpv3+/+ and Trpv3−/− mice as determined by western blot. (d) Double immunofluorescence staining of PAR2 (green) and TRPV3 (red) in mouse keratinocytes. Scale bar, 20 μm. (e) Venn diagram showing the overlapping of PAR2 and TRPV3 in mouse keratinocytes. *p < 0.05, **p < 0.01, ***p < 0.001. Data are presented as mean ± s.e.m.

    Journal: The Journal of investigative dermatology

    Article Title: PAR2 mediates itch via TRPV3 signaling in keratinocytes

    doi: 10.1016/j.jid.2020.01.012

    Figure Lengend Snippet: (a) Acute itch behaviors of Trpv3−/− mice and their WT littermates induced by intradermal injections of SLIGRL (50 μg), trypsin (100 μg), 2fly (10 μg), histamine (200 μg), and BAM 8-22 (150 μg). Unpaired t tests. n = 6–8. (b) WT mice were pre-injected with vehicle (Veh) (8% DMSO), 74a (150 μg, i.d.) or FSLLRY (100 μg, i.d.) 15 min before testing the scratching behaviors elicited by SLIGRL, trypsin, or 2fly. One-way ANOVA followed by Tukey’s post hoc. n = 6-8 mice per group. (c) TRPV3 expression in the skin and DRG of Trpv3+/+ and Trpv3−/− mice as determined by western blot. (d) Double immunofluorescence staining of PAR2 (green) and TRPV3 (red) in mouse keratinocytes. Scale bar, 20 μm. (e) Venn diagram showing the overlapping of PAR2 and TRPV3 in mouse keratinocytes. *p < 0.05, **p < 0.01, ***p < 0.001. Data are presented as mean ± s.e.m.

    Article Snippet: The primary antibodies used were goat anti-TRPV3 (Alomone Labs, 1:100) and goat anti-GAPDH (Leagene, 1:1000) antibodies.

    Techniques: Injection, Expressing, Western Blot, Double Immunofluorescence Staining

    (a) The percentages of responding keratinocytes from WT and Trpv3−/− mice stimulated with histamine (100 μM) and SLIGRL (50 μM). ***p < 0.001, unpaired t tests. n = 3 mice per group. (b) Representative fluorescence images of Fura2 (2 μM)-loaded WT, Trpv3−/− and Par2−/− keratinocytes stimulated with SLIGRL (50 μM). Scale bar, 20 μm. (c) Representative traces showing intracellular Ca2+ responses elicited by SLIGRL (50 μM) in WT mouse keratinocytes. (d, e) The effect of FSLLRY (100 μM) (d) and 74a (100 μM) (e) on SLIGRL-induced Ca2+ responses in WT mouse keratinocytes. (f) The effect of 74a (100 μM) on SLIGKV-induced (100 μM) Ca2+responses in human keratinocytes. (g) Quantified data showing the percentages of SLIGRL-responsive keratinocytes before and after the incubation of FSLLRY or 74a. ***p < 0.001, unpaired t test, n = 3 mice per group. Data are presented as mean ± s.e.m.

    Journal: The Journal of investigative dermatology

    Article Title: PAR2 mediates itch via TRPV3 signaling in keratinocytes

    doi: 10.1016/j.jid.2020.01.012

    Figure Lengend Snippet: (a) The percentages of responding keratinocytes from WT and Trpv3−/− mice stimulated with histamine (100 μM) and SLIGRL (50 μM). ***p < 0.001, unpaired t tests. n = 3 mice per group. (b) Representative fluorescence images of Fura2 (2 μM)-loaded WT, Trpv3−/− and Par2−/− keratinocytes stimulated with SLIGRL (50 μM). Scale bar, 20 μm. (c) Representative traces showing intracellular Ca2+ responses elicited by SLIGRL (50 μM) in WT mouse keratinocytes. (d, e) The effect of FSLLRY (100 μM) (d) and 74a (100 μM) (e) on SLIGRL-induced Ca2+ responses in WT mouse keratinocytes. (f) The effect of 74a (100 μM) on SLIGKV-induced (100 μM) Ca2+responses in human keratinocytes. (g) Quantified data showing the percentages of SLIGRL-responsive keratinocytes before and after the incubation of FSLLRY or 74a. ***p < 0.001, unpaired t test, n = 3 mice per group. Data are presented as mean ± s.e.m.

    Article Snippet: The primary antibodies used were goat anti-TRPV3 (Alomone Labs, 1:100) and goat anti-GAPDH (Leagene, 1:1000) antibodies.

    Techniques: Fluorescence, Incubation

    (a-c) Representative traces showing that Ca2+ transients elicited by SLIGRL (50 μM) in WT mouse keratinocytes were completely inhibited by co-incubation with 100 μM gallein, a Gβγ-protein inhibitor (a) and 10 μM U73122, a PLC inhibitor (b), but were partially inhibited by co-incubation with 10 μM DBHQ, an ATPase inhibitor (c). (d) Quantified data showing the percentages of SLIGRL-responsive keratinocytes before and after the incubation of gallein, U73122 or DBHQ. *p < 0.05, **p < 0.01, ***p < 0.001, unpaired t test, n = 3 mice per group. (e) TSLP in cultured media after SLIGRL stimulation was assayed by ELISA. Keratinocytes from Trpv3−/− and Par2−/− mice released less TSLP in response to SLIGRL stimulation. n = 3 mice per group. *p < 0.05, **p < 0.01, two-way ANOVA with Bonferroni post hoc test.

    Journal: The Journal of investigative dermatology

    Article Title: PAR2 mediates itch via TRPV3 signaling in keratinocytes

    doi: 10.1016/j.jid.2020.01.012

    Figure Lengend Snippet: (a-c) Representative traces showing that Ca2+ transients elicited by SLIGRL (50 μM) in WT mouse keratinocytes were completely inhibited by co-incubation with 100 μM gallein, a Gβγ-protein inhibitor (a) and 10 μM U73122, a PLC inhibitor (b), but were partially inhibited by co-incubation with 10 μM DBHQ, an ATPase inhibitor (c). (d) Quantified data showing the percentages of SLIGRL-responsive keratinocytes before and after the incubation of gallein, U73122 or DBHQ. *p < 0.05, **p < 0.01, ***p < 0.001, unpaired t test, n = 3 mice per group. (e) TSLP in cultured media after SLIGRL stimulation was assayed by ELISA. Keratinocytes from Trpv3−/− and Par2−/− mice released less TSLP in response to SLIGRL stimulation. n = 3 mice per group. *p < 0.05, **p < 0.01, two-way ANOVA with Bonferroni post hoc test.

    Article Snippet: The primary antibodies used were goat anti-TRPV3 (Alomone Labs, 1:100) and goat anti-GAPDH (Leagene, 1:1000) antibodies.

    Techniques: Incubation, Cell Culture, Enzyme-linked Immunosorbent Assay

    (a) WT, Trpv3−/− and Par2−/− mice were treated daily with a topical application of MC-903. Scratching numbers were recorded on day 1, 3, 5, and 7. Two-way ANOVA followed by Bonferroni post hoc. n = 6–8 mice per group. (b) Real time RT-PCR showing the relative levels of TRPV3 and PAR2 mRNA in pruritic skin lesions of AD patients and normal control. Unpaired t test. n = 12. (c, d) Relative levels of PAR2 mRNA (c) and TRPV3 mRNA (e) in the ears of MC-903-treated mice on day 5. Two-way ANOVA with Bonferroni post hoc. n = 4–5. Data are presented as mean ± s.e.m. *p < 0.05, **p < 0.01, ***p < 0.001.

    Journal: The Journal of investigative dermatology

    Article Title: PAR2 mediates itch via TRPV3 signaling in keratinocytes

    doi: 10.1016/j.jid.2020.01.012

    Figure Lengend Snippet: (a) WT, Trpv3−/− and Par2−/− mice were treated daily with a topical application of MC-903. Scratching numbers were recorded on day 1, 3, 5, and 7. Two-way ANOVA followed by Bonferroni post hoc. n = 6–8 mice per group. (b) Real time RT-PCR showing the relative levels of TRPV3 and PAR2 mRNA in pruritic skin lesions of AD patients and normal control. Unpaired t test. n = 12. (c, d) Relative levels of PAR2 mRNA (c) and TRPV3 mRNA (e) in the ears of MC-903-treated mice on day 5. Two-way ANOVA with Bonferroni post hoc. n = 4–5. Data are presented as mean ± s.e.m. *p < 0.05, **p < 0.01, ***p < 0.001.

    Article Snippet: The primary antibodies used were goat anti-TRPV3 (Alomone Labs, 1:100) and goat anti-GAPDH (Leagene, 1:1000) antibodies.

    Techniques: Quantitative RT-PCR

    (a-d) Ear appearance of WT mice topically applied with vehicle as a control (a), MC-903 (b), MC-903+74a (c), and MC-903+FSLLRY (d) for 7 days. (e-h) Hematoxylin-eosin staining showing changes in hyperkeratosis and inflammatory infiltration in the ears of corresponding mice in panels a-d, respectively. Scale = 50 μm. (i. j) The scratching numbers (i) and ear thickness increment (j) of mice treated with MC-903, MC-903+74a and MC-903+FSLLRY for 7 days. One-way ANOVA followed by Tukey’s post hoc. n = 6–8 mice per group. (k) Diagram illustrating PAR2-TRPV3 signaling pathway in itch.

    Journal: The Journal of investigative dermatology

    Article Title: PAR2 mediates itch via TRPV3 signaling in keratinocytes

    doi: 10.1016/j.jid.2020.01.012

    Figure Lengend Snippet: (a-d) Ear appearance of WT mice topically applied with vehicle as a control (a), MC-903 (b), MC-903+74a (c), and MC-903+FSLLRY (d) for 7 days. (e-h) Hematoxylin-eosin staining showing changes in hyperkeratosis and inflammatory infiltration in the ears of corresponding mice in panels a-d, respectively. Scale = 50 μm. (i. j) The scratching numbers (i) and ear thickness increment (j) of mice treated with MC-903, MC-903+74a and MC-903+FSLLRY for 7 days. One-way ANOVA followed by Tukey’s post hoc. n = 6–8 mice per group. (k) Diagram illustrating PAR2-TRPV3 signaling pathway in itch.

    Article Snippet: The primary antibodies used were goat anti-TRPV3 (Alomone Labs, 1:100) and goat anti-GAPDH (Leagene, 1:1000) antibodies.

    Techniques: Staining